JOYCE MASSEY TBI GRAND CHALLENGE
2016 Funded Research Projects

Funding was awarded based on the potential to impact the way traumatic brain injury is diagnosed and treated during the initial “golden hours” of care.

THE NEED

TRAUMATIC BRAIN INJURY + HEMORRHAGIC SHOCK = DOUBLE THE MORBIDITY & MORTALITY RATE

COMPETITIVE ADVANTAGE

PROVEN DATA
The team's preliminary data suggest that early administration of VPA can decrease the severity of TBI.

PORTABLE, LOW VOLUME, & EASY TO ADMINISTER
Can be widely incorporated into trauma resuscitation protocols, including on the battlefield where TBI is the “signature injury.”

NOVEL TBI THERAPY
There are currently no effective therapies for TBI patients. Valproic acid is well positioned to be the first.

THE TECHNOLOGY

VALPROIC ACID → NEUROPROTECTIVE MECHANISM → LESS SEVERE INJURY + MORE RAPID RECOVERY

Using genomic & proteomic tech to identify how valproic acid decreases the severity of TBI.

THE TEAM

Hasan Alam, MD
Acute Care Surgery

Patrick Georgoff, MD
General Surgery

Brian Athey, PhD
Computational Medicine and Bioinformatics

Gerald Higgins, MD, PhD
Computational Medicine and Bioinformatics

Vahagn Nikolian, MD
General Surgery

COMMERCIALIZATION ROADMAP

INVESTIGATIONAL NEW DRUG (IND) regulatory pathway

LICENSE TECHNOLOGY/ THERAPY

POTENTIAL PARTNERS
Drug companies

PROJECT MILESTONES

Utilize high throughput technology in injured animals

Identify valproic acid’s mechanism of action

Optimize dosing and timing for use in humans

Treat patients with TBI